Medical News

RSS

Multinational team identifies novel retinal disease gene

A multinational team effort of Regensburg's Institute of Human Genetics, Washington University in St. Louis, other partners and Genomatix elucidated a transcriptional network in photoreceptors and thereby identified a novel retinal disease gene

19 Nov 2010

National monitoring essential for preventing emergence of malaria drug resistance

WHO is calling on countries to be increasingly vigilant in monitoring antimalarial drug efficacy in order to allow for early detection of artemisinin resistance.1 This is one among several conclusions of the Global report on antimalarial drug efficacy and drug resistance: 2000-2010, released today. The report is based on 1100 studies conducted by national malaria control programs and research institutes over the ten-year period.

19 Nov 2010

Glutaminase inhibitor: New potential target for brain tumors

Scientists at Johns Hopkins have identified a compound that could be used to starve cancers of their sugar-based building blocks. The compound, called a glutaminase inhibitor, has been tested on laboratory cultured, sugar-hungry brain cancer cells and, the scientists say, may have the potential to be used for many types of primary brain tumors.

19 Nov 2010

Crescent Healthcare to open infusion pharmacy in New Jersey

Crescent Healthcare today announced a planned expansion of their east coast operations in 2011. They signed a lease to open an infusion pharmacy in Totowa, New Jersey, central to providing immune globulin therapies and services to current patients in Massachusetts, Maryland, New York, New Jersey, Pennsylvania, Connecticut, Delaware, District of Columbia, and Rhode Island.

19 Nov 2010

Kansas Attorney General-elect announces plans to fight health law in court

Challenges to the federal health law grow but a group of bipartisan lawmakers ask a judge in Florida to let them express support for the measure in that important case.

19 Nov 2010

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced results from a Phase 1b clinical trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, in patients with advanced gastrointestinal (GI) cancers.

19 Nov 2010

COG to conduct Phase I REOLYSIN trial in pediatric patients with solid tumors

Oncolytics Biotech Inc. announced today that the Children's Oncology Group (COG) intends to conduct a Phase I trial of REOLYSIN in combination with cyclophosphamide in pediatric patients with relapsed or refractory solid tumors.

19 Nov 2010

Scientists solve receptor structure that responds to neurotransmitter dopamine

A team led by scientists at The Scripps Research Institute has solved the structure of one of the receptors that responds to the neurotransmitter dopamine. Although dopamine transmission is essential to normal brain functioning, the biological assembly of the molecules involved in this crucial neuronal interplay had not been known until now.

19 Nov 2010

Zalicus presents data on novel synergistic drug combinations for cancer at EORTC-NCI-AACR Symposium

Zalicus Inc. presented data today on its discovery of novel synergistic drug combinations for the treatment of cancer at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Meeting in Berlin, Germany on November 18, 2010.

19 Nov 2010

IPS explores what efforts to reduce U.S. federal deficit could mean for global health funding

Inter Press Service explores some advocates' concerns over how the new emphasis in Washington on reducing government spending could affect U.S. funding for global health programs, including HIV/AIDS.

19 Nov 2010

3Sbio converts US$2.58 million debenture into Isotechnika Pharma

3SBio Inc. ("3SBio") (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products today announced that it has recently converted the remaining US$2.58 million of a US$4.5 million debenture convertible into Isotechnika Pharma Inc. ("Isotechnika") common shares issued on August 23, 2010.

19 Nov 2010

OXiGENE updates data on FALCON trial for non-small cell lung cancer

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT(TM) (CA4P) in patients with non-small cell lung cancer (NSCLC).

19 Nov 2010

Advanced Life Sciences submits application to FDA for ALS-886 to treat ARDS

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has applied to the U.S. Food and Drug Administration for orphan drug designation for ALS-886, a novel therapy to reduce and prevent tissue damage, for the treatment of Acute Respiratory Distress Syndrome (ARDS).

19 Nov 2010

YM BioSciences expands CYT387 Phase I/II clinical trial for myelofibrosis in five sites

YM BioSciences Inc., today reported that the Phase I/II clinical trial for its orally available JAK1/JAK2 inhibitor, CYT387, in patients with myelofibrosis has been expanded to five sites. Of the additional sites, the Stanford Cancer Center (Stanford, California) under Principal Investigator Jason Gotlib, MD has already commenced enrolling patients.

19 Nov 2010

Aastrom announces interim analysis of Phase 2b RESTORE-CLI clinical trial for treatment failure

Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that an interim analysis of all 86 patients enrolled in the company's Phase 2b RESTORE-CLI clinical trial shows that the study achieved both its primary safety endpoint and primary efficacy endpoint of time to first occurrence of treatment failure.

19 Nov 2010

Scientists discover bone matrix plays a vital role in tissue hardening

Scientists are reporting the first direct evidence that a subtle change in the physical properties of a tissue can affect its function. The finding has immediate implications for understanding several rare hearing disorders, they said, and ultimately could offer insight into such conditions as osteoporosis, arthritis, cardiovascular disease and cancer.

19 Nov 2010

St. Jude Medical completes acquisition of AGA Medical

St. Jude Medical, Inc. today announced that it has successfully completed its acquisition of AGA Medical Holdings, Inc.

19 Nov 2010

Bristol-Myers Squibb prices cash tender offer for $750 million

Bristol-Myers Squibb Company announced today the pricing terms of its previously announced cash tender offer for up to $750 million aggregate principal amount of certain of its outstanding debt securities.

19 Nov 2010

Study finds adverse long term health effects of E coli infection

People who contract gastroenteritis from drinking water contaminated with E coli are at an increased risk of developing high blood pressure, kidney problems and heart disease in later life, finds a study published online in the British Medical Journal.

19 Nov 2010

Ipsen initiates patient treatment in phase III OBI-1 study for acquired hemophilia A

Ipsen announced today that its partner Inspiration Biopharmaceuticals, Inc. has initiated treatment of patients in the first of two phase III pivotal clinical studies of OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product, for the treatment of acquired hemophilia A, a rare, though potentially life-threatening bleeding disorder.

19 Nov 2010

Medical News

Multinational team identifies novel retinal disease gene

National monitoring essential for preventing emergence of malaria drug resistance

Glutaminase inhibitor: New potential target for brain tumors

Crescent Healthcare to open infusion pharmacy in New Jersey

Kansas Attorney General-elect announces plans to fight health law in court

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

COG to conduct Phase I REOLYSIN trial in pediatric patients with solid tumors

Scientists solve receptor structure that responds to neurotransmitter dopamine

Zalicus presents data on novel synergistic drug combinations for cancer at EORTC-NCI-AACR Symposium

IPS explores what efforts to reduce U.S. federal deficit could mean for global health funding

3Sbio converts US$2.58 million debenture into Isotechnika Pharma

OXiGENE updates data on FALCON trial for non-small cell lung cancer

Advanced Life Sciences submits application to FDA for ALS-886 to treat ARDS

YM BioSciences expands CYT387 Phase I/II clinical trial for myelofibrosis in five sites

Aastrom announces interim analysis of Phase 2b RESTORE-CLI clinical trial for treatment failure

Scientists discover bone matrix plays a vital role in tissue hardening

St. Jude Medical completes acquisition of AGA Medical

Bristol-Myers Squibb prices cash tender offer for $750 million

Study finds adverse long term health effects of E coli infection

Ipsen initiates patient treatment in phase III OBI-1 study for acquired hemophilia A

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News